Home > Insider Trading > Filing (0001127602-20-019790)

Filing Details

Accession Number:: 0001127602-20-019790
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-16 18:16:32
Reporting Period:: 2020-06-12

Accepted Time:: 2020-06-16 18:16:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
313143	Haemonetics Corp	HAE	Surgical & Medical Instruments & Apparatus (3841)	042882273

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1682069	Mr. P. William Burke	125 Summer Street Boston MA 02110	Evp, Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-06-12	22,334	$0.00	35,029	No	4	A	Direct
Common Stock	Disposition	2020-06-12	197	$89.29	34,832	No	4	S	Direct
Common Stock	Disposition	2020-06-15	9,720	$87.71	25,112	No	4	S	Direct
Common Stock	Disposition	2020-06-16	5,259	$90.36	19,853	No	4	S	Direct
Common Stock	Disposition	2020-06-16	6,146	$91.38	13,707	No	4	S	Direct
Common Stock	Disposition	2020-06-16	1,209	$92.09	12,498	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020.
This number includes unvested restricted stock units ("RSUs") previously reported.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by thereporting person.
Transaction pursuant to an existing 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.94 to $90.94, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (6) through (8) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.95 to $91.95, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.97 to $92.24, inclusive.